Cadila Healthcare is reportedly in talks to acquire generic sterile injectables business of Claris Lifesciences (CLL). Cadila is likely to pay a hefty premium, valuing the company at Rs 3,100-3,400 crore. Both sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters.
For 12 months ended December 31, 2014, the injectables business posted revenues of Rs 405.6 crore and EBITDA of Rs 149.4 crore(37% EBITDA margin). Therefore, the business is being valued at over 22 times EV/EBITDA. To put it in perspective, the current market cap of parent CLL, including all the businesses, is Rs 1,793 crore.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: